A Multi-site study of Tamoxifen dose escalation study in breast cancer patients with CYP2D6 polymorphisms (TADE study) [ 2012 - 2016 ]

Research Grant

Researchers: Prof Howard Gurney (Principal investigator) ,  A/Pr Nicholas Wilcken ,  A/Pr Rosemary Balleine ,  Prof Christopher Liddle

Brief description Tamoxifen is a selective anti-oestrogenic medication commonly used to treat breast cancer. Recent evidence suggests that tamoxifen may not be adequately activated in the body of some people because of their genetic make-up, and that this may reduce its effectiveness. In this study of 120 women, we will determine whether increasing tamoxifen dosage is a useful strategy in people with low activation levels. This could provide practical guidance for patients and clinicians managing breast cancer.

Funding Amount $AUD 340,768.82

Funding Scheme Project Grants

Notes Standard Project Grant